EUVIMEDEUVIMED entdecken
KohortenstudieOpen Access · CC BY 4.0

SERPINE1 genotype and clinical outcomes during tezepelumab treatment in severe asthma: an exploratory prospective multicenter cohort study

Susumu Fukahori, Yasushi Obase, Chizu Fukushima, Kosuke Kosai, Katsunori Yanagihara, Shintaro Hara, Shinya Tomari, Hironobu Tsubouchi, Taiga Miyazaki, Nobuko Matsuo, Ayako Matsuo, Nobuhiro Matsumoto und 14 weitere

Frontiers in Allergy · 20.11.2026 · 7

DOI: 10.3389/falgy.2026.2016157 ↗

Kurz gefasst

Kohortenstudie in der Zeitschrift Frontiers in Allergy, online erschienen am 20.11.2026. Verfasst von Susumu Fukahori und 25 weiteren Autor:innen. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

SERPINE1 encodes plasminogen activator inhibitor-1 (PAI-1), a candidate contributor to airway inflammation and remodeling. We explored associations between the SERPINE1 −675 4G/5G polymorphism and outcomes during tezepelumab treatment.

Methods

This prospective multicenter cohort enrolled 45 Japanese adults; 44 completed 52 weeks (4G/4G, 21; 4G/5G, 15; 5G/5G, 8). Genotyping of pretreatment samples occurred after follow-up, with physicians and outcome assessors blinded to genotype. The approved protocol specified negative binomial regression comparing 4G carriers with 5G/5G, adjusted for prior-year exacerbations. Additional adjustment for prior biologic exposure, ICS category, and maintenance OCS use was retained as exploratory.

Results

Forty-seven exacerbations occurred over 44 patient-years, defining one analysis year as 52 weeks. Crude annualized exacerbation rates were 1.14, 0.73, and 1.50 events/patient-year across the three genotypes; 30 participants had no exacerbations. The protocol-specified adjusted incidence rate ratio was 5.06 (95% confidence interval, 0.51–49.97), compared with 0.65 (0.11–3.69) unadjusted and 3.28 (0.34–31.29) with expanded adjustment. These estimates were too imprecise and model-dependent for reliable interpretation. An exploratory three-genotype FeNO comparison at week 52 yielded P = 0.00353; post hoc false discovery rate adjustment gave q = 0.04594 across 13 secondary tests and q = 0.08127 across 23 secondary/exploratory tests. The 0.05 threshold was met only in the smaller family; both adjustments remain exploratory.

Conclusions

The data do not establish either a clinically useful genotype association or its absence. Sparse outcomes, baseline imbalance, and heterogeneous treatment histories limit inference. Without a comparator treatment, this study cannot determine whether genotype modifies the treatment effect of tezepelumab.

Trial registration

UMIN000052531, October 18, 2023.

Zitieren

APA

Fukahori, S., Obase, Y., Fukushima, C., Kosai, K., Yanagihara, K., Hara, S., Tomari, S., Tsubouchi, H., Miyazaki, T., Matsuo, N., Matsuo, A., Matsumoto, N., Ide, H., Tobino, K., Kodaka, N., Matsuse, H., Arakaki, W., Haranaga, S., Yamamoto, K., …, & Mukae, H. (2026). SERPINE1 genotype and clinical outcomes during tezepelumab treatment in severe asthma: an exploratory prospective multicenter cohort study. Frontiers in Allergy, 7. https://doi.org/10.3389/falgy.2026.2016157

Vancouver

Fukahori S, Obase Y, Fukushima C, Kosai K, Yanagihara K, Hara S, et al. SERPINE1 genotype and clinical outcomes during tezepelumab treatment in severe asthma: an exploratory prospective multicenter cohort study. Frontiers in Allergy. 2026;7. doi:10.3389/falgy.2026.2016157

BibTeX
@article{Fukahori2026,
  author = {Fukahori, Susumu and Obase, Yasushi and Fukushima, Chizu and Kosai, Kosuke and Yanagihara, Katsunori and Hara, Shintaro and Tomari, Shinya and Tsubouchi, Hironobu and Miyazaki, Taiga and Matsuo, Nobuko and Matsuo, Ayako and Matsumoto, Nobuhiro and Ide, Hiromi and Tobino, Kazunori and Kodaka, Norio and Matsuse, Hiroto and Arakaki, Wakako and Haranaga, Shusaku and Yamamoto, Kazuko and Yoshimine, Hiroyuki and Sakakibara, Hideki and Yatera, Kazuhiro and Tashiro, Hiroki and Takahashi, Koichiro and Himeji, Daisuke and Mukae, Hiroshi},
  title = {SERPINE1 genotype and clinical outcomes during tezepelumab treatment in severe asthma: an exploratory prospective multicenter cohort study},
  journal = {Frontiers in Allergy},
  year = {2026},
  volume = {7},
  doi = {10.3389/falgy.2026.2016157}
}
Kostenlos starten →